FTC challenges several big drugmakers over inaccurate or improper patent listings; FDA cites cancer links in seeking to withdraw approval of antibiotic used in pigs

Taking stock of the drug industry, from the lab to the medicine chest

November 7, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | FTC challenges several big drugmakers over inaccurate or improper patent listings "Wrongfully listed patents can significantly drive up the prices Americans must pay for medicines," said FTC chair Lina Khan. By Ed Silverman STAT+ | FDA cites cancer links in seeking to withdraw approval of antibiotic used in pigs The concern is that carcinogenic traces of the medicine can find their way into humans through pork in the food supply chain. By Ed Silverman STAT+ | Ventyx stock craters after lackluster mid-stage trial results for psoriasis drug The stock plunged after Ventyx said the drug did not meet internal goals to advance to the next phase of clinical development. By Jonathan Wosen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser